These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 23453297)

  • 1. Fluorescent in situ hybridization as a predictor of relapse in urothelial carcinoma.
    García-Peláez B; Trias I; Román R; Pubill C; Banús JM; Puig X
    Actas Urol Esp; 2013; 37(7):395-400. PubMed ID: 23453297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermediate-risk urothelial carcinoma: an unresolved problem?
    Pycha A; Lodde M; Comploj E; Negri G; Egarter-Vigl E; Vittadello F; Lusuardi L; Palermo S; Mian C
    Urology; 2004 Mar; 63(3):472-5. PubMed ID: 15028440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
    Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
    Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of urothelial carcinoma of the urinary bladder by multicolor fluorescence in situ hybridization].
    Zhang YG; Bi XG; Han YL; Cai Y; Xu X; Wu YP; Yang YL; Ma JH; Zhao P; Jia XM; Wang MR
    Ai Zheng; 2007 Feb; 26(2):189-93. PubMed ID: 17298751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology.
    Kawauchi S; Sakai H; Ikemoto K; Eguchi S; Nakao M; Takihara H; Shimabukuro T; Furuya T; Oga A; Matsuyama H; Takahashi M; Sasaki K
    Hum Pathol; 2009 Dec; 40(12):1783-9. PubMed ID: 19733894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UroVysion® multiprobe FISH in the triage of equivocal urinary cytology cases.
    Bubendorf L; Piaton E
    Ann Pathol; 2012 Dec; 32(6):e52-6, 438-43. PubMed ID: 23244486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.
    Moonen PM; Merkx GF; Peelen P; Karthaus HF; Smeets DF; Witjes JA
    Eur Urol; 2007 May; 51(5):1275-80; discussion 1280. PubMed ID: 17084511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.
    Lodde M; Mian C; Mayr R; Comploj E; Trenti E; Melotti R; Campodonico F; Maffezzini M; Fritsche HM; Pycha A
    Int J Urol; 2014 Oct; 21(10):968-72. PubMed ID: 24947145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.
    Veeramachaneni R; Nordberg ML; Shi R; Herrera GA; Turbat-Herrera EA
    Diagn Cytopathol; 2003 Jun; 28(6):301-7. PubMed ID: 12768634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer.
    Sarosdy MF; Schellhammer P; Bokinsky G; Kahn P; Chao R; Yore L; Zadra J; Burzon D; Osher G; Bridge JA; Anderson S; Johansson SL; Lieber M; Soloway M; Flom K
    J Urol; 2002 Nov; 168(5):1950-4. PubMed ID: 12394683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer?
    Bollmann M; Heller H; Bánkfalvi A; Griefingholt H; Bollmann R
    BJU Int; 2005 Jun; 95(9):1219-25. PubMed ID: 15892805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder.
    Fritsche HM; Burger M; Dietmaier W; Denzinger S; Bach E; Otto W; Doblinger M; Schwarz S; Buchner H; Hartmann A
    Am J Clin Pathol; 2010 Oct; 134(4):597-603. PubMed ID: 20855641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
    Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
    Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Numerical aberrations of chromosomes 11 and 17 detected by fish--fluorescence in situ hybridization combined with cytology in exfoliated cells from voided urine in patients with urothelial carcinoma of the bladder].
    Asali MG; Kaneti J; Manor E
    Harefuah; 2007 Dec; 146(12):914-9, 1000. PubMed ID: 18254439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosomal abnormalities in renal cell carcinoma variants detected by Urovysion fluorescence in situ hybridization on paraffin-embedded tissue.
    Reid-Nicholson MD; Motiwala N; Drury SC; Peiper SC; Terris MK; Waller JL; Ramalingam P
    Ann Diagn Pathol; 2011 Feb; 15(1):37-45. PubMed ID: 21238914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
    Bergman J; Reznichek RC; Rajfer J
    BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified UroVysion scoring criteria increase the urothelial carcinoma detection rate in cases of equivocal urinary cytology.
    Huysentruyt CJ; Baldewijns MM; Rüland AM; Tonk RJ; Vervoort PS; Smits KM; van de Beek C; Speel EJ
    Histopathology; 2011 Jun; 58(7):1048-53. PubMed ID: 21707706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.
    Lotan Y; Bensalah K; Ruddell T; Shariat SF; Sagalowsky AI; Ashfaq R
    J Urol; 2008 Jun; 179(6):2164-9. PubMed ID: 18423745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.